Iptacopan: First Approval.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 15 citations in OpenAlex.

1. Synthetic strategies and therapeutic insights into FDA-approved indole-containing drugs.Journal of enzyme inhibition and medicinal chemistry · 2026
   Review
2. Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?European journal of immunology · 2026
   Review
3. Meningococcal Serogroup Y Meningitis Reveals Inborn Factor B Deficiency.European journal of immunology · 2026
   Article
4. Integrative miRNA-mRNA Network and Molecular Dynamics-Based Identification of Therapeutic Candidates for Paroxysmal Nocturnal Hemoglobinuria.Pharmaceuticals (Basel, Switzerland) · 2026
   Article
5. [How I diagnose and treat paroxysmal nocturnal hemoglobinuria].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
   Article
6. New Anticomplement Drugs in Nephrology: Mechanism and Indication.Kidney & blood pressure research · 2026
   Review
7. Mechanistic Insights and Therapeutic Advances of Anti-Inflammatory Biologics in Immune-Mediated Glomerulonephritis: A Narrative Review.Journal of inflammation research · 2026
   Review
8. Beyond Terminal Blockade: A Mechanism-Based Approach to Complement Inhibitor Selection in Paroxysmal Nocturnal Hemoglobinuria.Drug design, development and therapy · 2026
   Review
9. Research Progress in Pharmacological Targeted Therapy for Myasthenia Gravis.Journal of inflammation research · 2026
   Review
10. The complement cascade in Alzheimer's disease: modern implications of an ancient immune protagonist.Molecular neurodegeneration · 2025
    Review
11. M28 family peptidase derived fromGut microbes · 2025
    Article
12. Treatment of transplantation-associated thrombotic microangiopathy with iptacopan: two cases report.Annals of hematology · 2025
    Article
13. Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies.Diseases (Basel, Switzerland) · 2025
    Review
14. Clinical characteristics and management of paroxysmal nocturnal hemoglobinuria in the Middle East: a narrative review.Clinical and experimental medicine · 2025
    Review
15. Complement System Inhibitors in Nephrology: An Update-Narrative Review.International journal of molecular sciences · 2025
    Review
16. Immunotargets and Therapy for Systemic Lupus Erythematosus.ImmunoTargets and therapy · 2025
    Review
17. [Interpretation of the guidelines for diagnosing and treating paroxysmal nocturnal hemoglobinuria in China (2024)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024
    Article
18. Apical tubular complement activation and the loss of kidney function in proteinuric kidney diseases.Clinical kidney journal · 2024
    Review

Corrections and comments

• Erratum issued
  Correction: Iptacopan: First Approval.2024

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as